Three-year clinical outcome with the endeavor TM zotarolimus-eluting stent in primary percutaneous coronary intervention for ST elevation myocardial infarction: The Endeavor TM primary PCI study (E-PPCI)

Journal of Interventional Cardiology

Volumn 24, Issue 6, 2011, Pages 542-548

  Shelton, Rhidian J ^a   Chitkara, Kamal ^a   Singh, Ravi ^a   Dorsch, Micha F ^a   Somers, Kathryn ^a   McLenachan, James M ^a   Blaxill, Jonathan M ^a   Wheatcroft, Stephen B ^a   Blackman, Daniel J ^a   Greenwood, John P ^a  

^a LEEDS GENERAL INFIRMARY   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ABCIXIMAB; ACETYLSALICYLIC ACID; CLOPIDOGREL; HEPARIN; PACLITAXEL; RAPAMYCIN; ZOTAROLIMUS;

ADULT; ARTICLE; BALLOON; COHORT ANALYSIS; DRUG ELUTING STENT; FEMALE; HEART MUSCLE REVASCULARIZATION; HUMAN; INCIDENCE; MAJOR CLINICAL STUDY; MALE; PERCUTANEOUS CORONARY INTERVENTION; PRIORITY JOURNAL; PROSPECTIVE STUDY; ST SEGMENT ELEVATION MYOCARDIAL INFARCTION; STENT THROMBOSIS; SYMPTOM; TREATMENT OUTCOME;

ANGIOPLASTY, BALLOON, CORONARY; ANTICOAGULANTS; ASPIRIN; CONFIDENCE INTERVALS; DRUG-ELUTING STENTS; FEMALE; GREAT BRITAIN; HEPARIN; HUMANS; IMMUNOSUPPRESSIVE AGENTS; MALE; MIDDLE AGED; MYOCARDIAL INFARCTION; PLATELET AGGREGATION INHIBITORS; PROSPECTIVE STUDIES; SIROLIMUS; TICLOPIDINE; TIME FACTORS; TREATMENT OUTCOME;

EID: 83955162914     PISSN: 08964327     EISSN: 15408183     Source Type: Journal    
DOI: 10.1111/j.1540-8183.2011.00674.x     Document Type: Article

References (41)

1. Boersma E,. Does time matter? A pooled analysis of randomized clinical trials comparing primary percutaneous coronary intervention and in-hospital fibrinolysis in acute myocardial infarction patients. Eur Heart J 2006; 27 (7): 779-788.
2. Boersma E, Maas AC, Deckers JW, et al,. Early thrombolytic treatment in acute myocardial infarction: Reappraisal of the golden hour. Lancet 1996; 348 (9030): 771-775. (Pubitemid 26308479)
3. Widimsky P, Bilkova D, Penicka M, et al,. Long-term outcomes of patients with acute myocardial infarction presenting to hospitals without catheterization laboratory and randomized to immediate thrombolysis or interhospital transport for primary percutaneous coronary intervention. Five years' follow-up of the PRAGUE-2 Trial. Eur Heart J 2007; 28 (6): 679-684. (Pubitemid 46439233)
4. Keeley EC, Boura JA, Grines CL,. Primary angioplasty versus intravenous thrombolytic therapy for acute myocardial infarction: A quantitative review of 23 randomised trials. Lancet 2003; 361 (9351): 13-20. (Pubitemid 36050955)
5. Kirtane AJ, Gupta A, Iyengar S, et al,. Safety and efficacy of drug-eluting and bare metal stents. Comprehensive meta-analysis of randomized trials and observational studies. Circulation 2009; 119 (25): 3198-3206.
6. Nakazawa G, Finn AV, Joner M, et al,. Delayed arterial healing and increased late stent thrombosis at culprit sites after drug-eluting stent placement for acute myocardial infarction patients: An autopsy study. Circulation 2008; 118 (11): 1138-1145.
7. Daemen J, Tanimoto S, Garcia-Garcia HM, et al,. Comparison of three-year clinical outcome of sirolimus- and paclitaxel-eluting stents versus bare metal stents in patients with ST-segment elevation myocardial infarction (from the RESEARCH and T-SEARCH Registries). Am J Cardiol 2007; 99 (8): 1027-1032. (Pubitemid 46560473)
8. De Luca G, Stone GW, Suryapranata H, et al,. Efficacy and safety of drug-eluting stents in ST-segment elevation myocardial infarction: A meta-analysis of randomized trials. Int J Cardiol 2009; 133 (2): 213-222.
9. Spaulding C, Rosencher J, Varenne O,. Use of drug eluting stents in ST segment elevation myocardial infarction. Heart 2010; 96 (13): 1073-1077.
10. Chen YW, Smith ML, Sheets M, et al,. Zotarolimus, a novel sirolimus analogue with potent anti-proliferative activity on coronary smooth muscle cells and reduced potential for systemic immunosuppression. J Cardiovasc Pharmacol 2007; 49 (4): 228-235. (Pubitemid 46626015)
11. Garcia-Touchard A, Burke SE, Toner JL, et al,. Zotarolimus-eluting stents reduce experimental coronary artery neointimal hyperplasia after 4 weeks. Eur Heart J 2006; 27 (8): 988-993.
12. Meredith IT, Ormiston J, Whitbourn R, et al,. First-in-human study of the Endeavor ABT-578-eluting phosphorylcholine-encapsulated stent system in de novo native coronary artery lesions: Endeavor I Trial. EuroIntervention 2005; 1 (2): 157-164.
13. Fajadet J, Wijns W, Laarman GJ, et al,. Randomized, double-blind, multicenter study of the Endeavor zotarolimus-eluting phosphorylcholine- encapsulated stent for treatment of native coronary artery lesions: Clinical and angiographic results of the ENDEAVOR II trial. Circulation 2006; 114 (8): 798-806. (Pubitemid 44268230)
14. Schultheiss HP, Grube E, Kuck KH, et al,. Safety of direct stenting with the Endeavor stent: Results of the Endeavor II continued access registry. EuroIntervention 2007; 3 (1): 76-81.
15. Kandzari DE, Leon MB, Popma JJ, et al,. Comparison of zotarolimus-eluting and sirolimus-eluting stents in patients with native coronary artery disease: A randomized controlled trial. J Am Coll Cardiol 2006; 48 (12): 2440-2447. (Pubitemid 44881222)
16. Leon MB, Mauri L, Popma JJ, et al,. A randomized comparison of the ENDEAVOR zotarolimus-eluting stent versus the TAXUS paclitaxel-eluting stent in de novo native coronary lesions 12-month outcomes from the ENDEAVOR IV trial. J Am Coll Cardiol. 55 (6): 543-554.
17. Lotan C, Meredith IT, Mauri L, et al,. Safety and effectiveness of the Endeavor zotarolimus-eluting stent in real-world clinical practice: 12-month data from the E-Five registry. JACC Cardiovasc Interv 2009; 2 (12): 1227-1235.
18. Van de Werf F, Bax J, Betriu A, et al,. Management of acute myocardial infarction in patients presenting with persistent ST-segment elevation: The Task Force on the Management of ST-Segment Elevation Acute Myocardial Infarction of the European Society of Cardiology. Eur Heart J 2008; 29 (23): 2909-2945.
19. Cutlip DE, Windecker S, Mehran R, et al,. Clinical end points in coronary stent trials: A case for standardized definitions. Circulation 2007; 115 (17): 2344-2351. (Pubitemid 46685903)
20. Valgimigli M, Percoco G, Malagutti P, et al,. Tirofiban and sirolimus-eluting stent vs abciximab and bare-metal stent for acute myocardial infarction: A randomized trial. JAMA 2005; 293 (17): 2109-2117. (Pubitemid 40617063)
21. Valgimigli M, Campo G, Percoco G, et al,. Comparison of angioplasty with infusion of tirofiban or abciximab and with implantation of sirolimus-eluting or uncoated stents for acute myocardial infarction: The MULTISTRATEGY randomized trial. JAMA 2008; 299 (15): 1788-1799. (Pubitemid 351549970)
22. Spaulding C, Henry P, Teiger E, et al,. Sirolimus-eluting versus uncoated stents in acute myocardial infarction. N Engl J Med 2006; 355 (11): 1093-1104. (Pubitemid 44394916)
23. van der Hoeven BL, Liem SS, Jukema JW, et al,. Sirolimus-eluting stents versus bare-metal stents in patients with ST-segment elevation myocardial infarction: 9-month angiographic and intravascular ultrasound results and 12-month clinical outcome results from the MISSION! Intervention Study. J Am Coll Cardiol 2008; 51 (6): 618-626. (Pubitemid 351186867)
24. Menichelli M, Parma A, Pucci E, et al,. Randomized trial of sirolimus-eluting stent versus bare-metal stent in acute myocardial infarction (SESAMI). J Am Coll Cardiol 2007; 49 (19): 1924-1930. (Pubitemid 46694284)
25. Stone GW, Lansky AJ, Pocock SJ, et al,. Paclitaxel-eluting stents versus bare-metal stents in acute myocardial infarction. N Engl J Med 2009; 360 (19): 1946-1959.
26. Brar SS, Leon MB, Stone GW, et al,. Use of drug-eluting stents in acute myocardial infarction: A systematic review and meta-analysis. J Am Coll Cardiol 2009; 53 (18): 1677-1689.
27. Violini R, Musto C, De Felice F, et al,. Maintenance of long-term clinical benefit with sirolimus-eluting stents in patients with ST-segment elevation myocardial infarction 3-year results of the SESAMI (sirolimus-eluting stent versus bare-metal stent in acute myocardial infarction) trial. J Am Coll Cardiol 2010; 55 (8): 810-814.
28. Spaulding C, Teiger E, Commeau P, et al,. Four-year follow-up of TYPHOON (Trial to Assess the Use of the CYPHer Sirolimus-Eluting Coronary Stent in Acute Myocardial Infarction Treated With BallOON Angioplasty). JACC: Cardiovasc Interv 2011; 4 (1): 14-23.
29. Di Lorenzo E, Sauro R, Varricchio A, et al,. Long-term outcome of drug-eluting stents compared with bare metal stents in ST-segment elevation myocardial infarction: Results of the paclitaxel- or sirolimus-eluting stent versus bare metal stent in Primary Angioplasty (PASEO) Randomized Trial. Circulation 2009; 120 (11): 964-972.
30. Lee CW, Park DW, Lee SH, et al,. Comparison of the efficacy and safety of zotarolimus-, sirolimus-, and paclitaxel-eluting stents in patients with ST-elevation myocardial infarction. Am J Cardiol 2009; 104 (10): 1370-1376.
31. Kim HK, Jeong MH, Ahn YK, et al,. Comparison of outcomes between Zotarolimus- and sirolimus-eluting stents in patients with ST-segment elevation acute myocardial infarction. Am J Cardiol. 105 (6): 813-818.
32. Lotan C,. Outcomes in patients undergoing primary PCI for STEMI vs. non-STEMI from the E-Five Registry. Abstract presented at EuroPCR Conference, Barcelona, Spain, May 2009.
33. McFadden EP, Stabile E, Regar E, et al,. Late thrombosis in drug-eluting coronary stents after discontinuation of antiplatelet therapy. Lancet 2004; 364 (9444): 1519-1521. (Pubitemid 39410418)
34. Joner M, Finn AV, Farb A, et al,. Pathology of drug-eluting stents in humans: Delayed healing and late thrombotic risk. J Am Coll Cardiol 2006; 48 (1): 193-202. (Pubitemid 43929240)
35. Cook S, Ladich E, Nakazawa G, et al,. Correlation of intravascular ultrasound findings with histopathological analysis of thrombus aspirates in patients with very late drug-eluting stent thrombosis. Circulation 2009; 120 (5): 391-399.
36. Miyazawa A, Ako J, Hongo Y, et al,. Comparison of vascular response to zotarolimus-eluting stent versus sirolimus-eluting stent: Intravascular ultrasound results from ENDEAVOR III. Am Heart J 2008; 155 (1): 108-113. (Pubitemid 350234763)
37. Waseda K, Miyazawa A, Ako J, et al,. Intravascular ultrasound results from the ENDEAVOR IV trial: Randomized comparison between zotarolimus- and paclitaxel-eluting stents in patients with coronary artery disease. JACC Cardiovasc Interv 2009; 2 (8): 779-784.
38. Sakurai R, Bonneau HN, Honda Y, et al,. Intravascular ultrasound findings in ENDEAVOR II and ENDEAVOR III. Am J Cardiol 2007; 100 (8B): 71M-76M.
39. Cook S, Wenaweser P, Togni M, et al,. Incomplete stent apposition and very late stent thrombosis after drug-eluting stent implantation. Circulation 2007; 115 (18): 2426-2434. (Pubitemid 46717965)
40. Camenzind E, Wijns W, Mauri L, et al,. Rationale and design of the Patient Related OuTcomes with Endeavor versus Cypher stenting Trial (PROTECT): Randomized controlled trial comparing the incidence of stent thrombosis and clinical events after sirolimus or zotarolimus drug-eluting stent implantation. Am Heart J 2009; 158 (6): 902-909; e5.
41. Atary JZ, van der Hoeven BL, Liem SS, et al,. Three-year outcome of sirolimus-eluting versus bare-metal stents for the treatment of ST-segment elevation myocardial infarction (from the MISSION! Intervention Study). Am J Cardiol 2010; 106 (1): 4-12.